Definitive Contract 75N91024C00061

Award Date 9/16/24
Potential Completion Date 9/15/25
Potential Value $388K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Raleigh, NC 27601, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This definitive contract from the Department of Health and Human Services' National Institutes of Health National Cancer Institute awards $377,530 to Gradient Health, Inc., doing business as Gradient Health, for TOPIC 454 - SOFTWARE TO EVALUATE ARTIFICIAL INTELLIGENCE/MACHINE LEARNING MEDICAL DEVICES IN ONCOLOGY SETTINGS. The prime contractor will perform work in Raleigh, North Carolina under a firm fixed price contract lasting from August 15, 2023 to August 14, 2024. This award stems from a...
This is a $455,000 firm fixed price contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS). The contract was awarded to Mrimath LLC, a small disadvantaged, woman-owned limited liability company, for a Small Business Innovation Research (SBIR) Phase I project related to Artificial Intelligence-aided imaging for cancer prevention, diagnosis, and monitoring. The contract has a...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This $399,951 firm-fixed-price definitive contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the small business Care Progress LLC. The contract supports the development of "BIOMARKERAWARE: A NOVEL SYSTEM TO IMPROVE PRECISION ONCOLOGY" under the NCI's Small Business Innovation Research (SBIR) program, which is a set-aside for small businesses. Care Progress LLC, a for-profit limited liability company, has previously...
This firm fixed price contract for $454,999 was awarded by the National Institutes of Health National Cancer Institute to Pathodynamics LLC, a minority-owned small disadvantaged business, to advance Topic 438 from the agency's Small Business Innovation Research program solicitation. Topic 438 sought technologies to aid community providers in understanding cancer patients' genomic test results. The contract supports the development of applications to help oncology practitioners interpret...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Pieces Technologies Inc., a small business, under the Small Business Innovation Research (SBIR) Phase II program. The contract, worth $1,999,994.00, is for the project titled "Passive and Active AI Screening for Social Determinants of Health and Interventions to Improve Outcomes in the Cancer Patient Population." The contract has a period of performance from September 16,...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...
This is a $398,604.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded to Infotech Soft, Inc. (a woman-owned for-profit organization) by the National Cancer Institute. The contract is for the development of quantitative imaging software tools to assist with cancer diagnosis and treatment planning. The contract is a definitive, firm fixed-price agreement, indicating a well-defined scope of work. This SBIR award is part of the National Cancer Institute's efforts to...

This is a $388,108 firm-fixed price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Gradient Health, Inc., a minority-owned small business. The contract is for a research and development project titled "Advancing Equity and Diversity in Breast Cancer Screening: Creating a Foundational Dataset and Toolset." This award is part of the NIH and Centers for Disease Control and Prevention (CDC) Small Business Innovation Research (SBIR) program, which aims to stimulate innovation and support the participation of small businesses in federal research and development. The contract has a period of performance through September 15, 2025.

Generated 11/27/24, 9:24 AM